NEOPRISM-CRC: Neoadjuvant pembrolizumab stratified to tumor mutation burden for high-risk stage 2 or stage 3 deficient-MMR/MSI-high colorectal cancer.

Shiu, K-K, Seligmann, JF orcid.org/0000-0003-4379-6005, Graham, J et al. (15 more authors) (2022) NEOPRISM-CRC: Neoadjuvant pembrolizumab stratified to tumor mutation burden for high-risk stage 2 or stage 3 deficient-MMR/MSI-high colorectal cancer. In: Journal of Clinical Oncology. 2022 ASCO Annual Meeting I, 03-07 Jun 2022, Chicago, USA. American Society of Clinical Oncology .

Metadata

Authors/Creators:
  • Shiu, K-K
  • Seligmann, JF ORCID logo https://orcid.org/0000-0003-4379-6005
  • Graham, J
  • Wilson, RH
  • Saunders, MP
  • Iveson, T
  • Kayhanian, H
  • Khan, KH
  • Rodriguez-Justo, M
  • Jansen, M
  • Obichere, A
  • Plumb, A
  • Seward, E
  • Irvine, S
  • Wilson, W
  • Bhat, R
  • Forsyth, S
  • White, L
Dates:
  • Published (online): 2 June 2022
  • Published: 1 June 2022
Institution: The University of Leeds
Funding Information:
FunderGrant number
Cancer Research UK Supplier No: 138573C7852/A19772
Depositing User: Symplectic Publications
Date Deposited: 27 Apr 2023 11:05
Last Modified: 27 Apr 2023 11:05
Status: Published
Publisher: American Society of Clinical Oncology
Identification Number: https://doi.org/10.1200/JCO.2022.40.16_suppl.TPS3645
Related URLs:

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Export

Statistics


CORE (COnnecting REpositories)